Difference between revisions of "Docetaxel (Taxotere)"
Jump to navigation
Jump to search
m (→References) |
m |
||
Line 28: | Line 28: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | *5/14/1996: Initial FDA approval for treatment of patients with locally advanced or metastatic [[Breast cancer | breast cancer]] who have progressed during [http://hemonc.org/wiki/Category:Anthracyclines anthracycline-based] therapy or have relapsed during [ | + | *5/14/1996: Initial FDA approval for treatment of patients with locally advanced or metastatic [[Breast cancer | breast cancer]] who have progressed during [http://hemonc.org/wiki/Category:Anthracyclines anthracycline-based] therapy or have relapsed during [[:Category:Anthracyclines|anthracycline-based]] adjuvant therapy. |
*6/22/1998: Breast cancer indication revised for the treatment of patients with locally advanced or metastatic [[Breast cancer | breast cancer]] after failure of prior chemotherapy. | *6/22/1998: Breast cancer indication revised for the treatment of patients with locally advanced or metastatic [[Breast cancer | breast cancer]] after failure of prior chemotherapy. | ||
− | *12/23/1999: Label expanded to include treatment of patients with locally advanced or metastatic [[Non-small cell lung cancer | non-small cell lung cancer]] after failure of prior [ | + | *12/23/1999: Label expanded to include treatment of patients with locally advanced or metastatic [[Non-small cell lung cancer | non-small cell lung cancer]] after failure of prior [[:Category:Platinum_agents | platinum-based]] chemotherapy. |
*11/27/2002: Lung cancer indication revised: | *11/27/2002: Lung cancer indication revised: | ||
− | ** As a single agent, is indicated for the treatment of patients with locally advanced or metastatic [[Non-small cell lung cancer | non-small cell lung cancer]] after failure of prior [ | + | ** As a single agent, is indicated for the treatment of patients with locally advanced or metastatic [[Non-small cell lung cancer | non-small cell lung cancer]] after failure of prior [[:Category:Platinum_agents | platinum-based]] chemotherapy. |
** In combination with [[Cisplatin (Platinol) | cisplatin]] is indicated for the treatment of patients with unresectable, locally advanced or metastatic [[Non-small cell lung cancer | non-small cell lung cancer]] who have not previously received chemotherapy for this condition. | ** In combination with [[Cisplatin (Platinol) | cisplatin]] is indicated for the treatment of patients with unresectable, locally advanced or metastatic [[Non-small cell lung cancer | non-small cell lung cancer]] who have not previously received chemotherapy for this condition. | ||
*5/19/2004: Label expanded as follows: in combination with [[Prednisone (Sterapred) | prednisone]] is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic [[Prostate cancer | prostate cancer]]. | *5/19/2004: Label expanded as follows: in combination with [[Prednisone (Sterapred) | prednisone]] is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic [[Prostate cancer | prostate cancer]]. | ||
Line 97: | Line 97: | ||
[[Category:Drugs FDA approved in 1996]] | [[Category:Drugs FDA approved in 1996]] | ||
+ | [[Category:WHO Essential Cancer Medicine]] |
Revision as of 18:43, 5 June 2016
General information
Class/mechanism: Taxane; disrupts normal microtubular function. Binds to free tubulin, promotes their assembly into stable microtubules, and inhibits their disassembly, which inhibits mitosis.[1][2]
Route: IV
Extravasation: irritant, rare vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Bone cancer
- Breast cancer
- Cervical cancer
- Esophageal cancer
- Gastric cancer
- Head and neck cancer
- Melanoma
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Sarcoma
- Small cell lung cancer
- Unknown primary
Patient drug information
- Docetaxel (Taxotere) patient drug information (Chemocare)[3]
- Docetaxel (Taxotere) package insert pages 16-17[1]
- Docetaxel (Taxotere) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/14/1996: Initial FDA approval for treatment of patients with locally advanced or metastatic breast cancer who have progressed during anthracycline-based therapy or have relapsed during anthracycline-based adjuvant therapy.
- 6/22/1998: Breast cancer indication revised for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
- 12/23/1999: Label expanded to include treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
- 11/27/2002: Lung cancer indication revised:
- As a single agent, is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
- In combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
- 5/19/2004: Label expanded as follows: in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.
- 8/18/2004: Breast cancer indication expanded: in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
- 3/22/2006: Label expanded as follows: in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.
- 10/17/2006: Label expanded as follows: in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Also known as
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Asodocel | Docetax | Docetaxel Comp | Docetaxel Delta Farma | Docetaxel Microsules | |||
Docetaxel Sandoz | Docetere | Dolectran | Doxel | Doxetal | |||
Oncodocel | Plustaxano | N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl Taxol | Neocel | NSC 628503 | |||
RP 56976 | Taxotere Aventis | Taxotere Chugai | Texot | Trixotene |
References
Categories:
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Irritant chemotherapy
- Vesicant chemotherapy
- Microtubule inhibitors
- Taxanes
- Bone cancer medications
- Breast cancer medications
- Cancer of unknown primary medications
- Cervical cancer medications
- Esophageal cancer medications
- Gastric cancer medications
- Head and neck cancer medications
- Melanoma medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Prostate cancer medications
- Sarcoma medications
- Small cell lung cancer medications
- Drugs FDA approved in 1996
- WHO Essential Cancer Medicine